148 related articles for article (PubMed ID: 14966891)
1. Reactivity-based one-pot synthesis of oligomannoses: defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody.
Lee HK; Scanlan CN; Huang CY; Chang AY; Calarese DA; Dwek RA; Rudd PM; Burton DR; Wilson IA; Wong CH
Angew Chem Int Ed Engl; 2004 Feb; 43(8):1000-3. PubMed ID: 14966891
[No Abstract] [Full Text] [Related]
2. Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design.
Wang LX; Ni J; Singh S; Li H
Chem Biol; 2004 Jan; 11(1):127-34. PubMed ID: 15113002
[TBL] [Abstract][Full Text] [Related]
3. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.
Calarese DA; Scanlan CN; Zwick MB; Deechongkit S; Mimura Y; Kunert R; Zhu P; Wormald MR; Stanfield RL; Roux KH; Kelly JW; Rudd PM; Dwek RA; Katinger H; Burton DR; Wilson IA
Science; 2003 Jun; 300(5628):2065-71. PubMed ID: 12829775
[TBL] [Abstract][Full Text] [Related]
4. A solution NMR study of the interactions of oligomannosides and the anti-HIV-1 2G12 antibody reveals distinct binding modes for branched ligands.
Enríquez-Navas PM; Marradi M; Padro D; Angulo J; Penadés S
Chemistry; 2011 Feb; 17(5):1547-60. PubMed ID: 21268157
[TBL] [Abstract][Full Text] [Related]
5. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12.
Calarese DA; Lee HK; Huang CY; Best MD; Astronomo RD; Stanfield RL; Katinger H; Burton DR; Wong CH; Wilson IA
Proc Natl Acad Sci U S A; 2005 Sep; 102(38):13372-7. PubMed ID: 16174734
[TBL] [Abstract][Full Text] [Related]
6. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged.
Doores KJ; Fulton Z; Huber M; Wilson IA; Burton DR
J Virol; 2010 Oct; 84(20):10690-9. PubMed ID: 20702629
[TBL] [Abstract][Full Text] [Related]
7. Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12.
Karpenko LI; Scherbakova NS; Chikaev AN; Tumanova OY; Lebedev LR; Shalamova LA; Pyankova OG; Ryzhikov AB; Ilyichev AA
Mol Immunol; 2012 Apr; 50(4):193-9. PubMed ID: 22341130
[TBL] [Abstract][Full Text] [Related]
8. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.
Huskens D; Van Laethem K; Vermeire K; Balzarini J; Schols D
Virology; 2007 Apr; 360(2):294-304. PubMed ID: 17123566
[TBL] [Abstract][Full Text] [Related]
9. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield.
Pejchal R; Doores KJ; Walker LM; Khayat R; Huang PS; Wang SK; Stanfield RL; Julien JP; Ramos A; Crispin M; Depetris R; Katpally U; Marozsan A; Cupo A; Maloveste S; Liu Y; McBride R; Ito Y; Sanders RW; Ogohara C; Paulson JC; Feizi T; Scanlan CN; Wong CH; Moore JP; Olson WC; Ward AB; Poignard P; Schief WR; Burton DR; Wilson IA
Science; 2011 Nov; 334(6059):1097-103. PubMed ID: 21998254
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades.
Zhang MY; Shu Y; Sidorov I; Dimitrov DS
Antiviral Res; 2004 Mar; 61(3):161-4. PubMed ID: 15168796
[TBL] [Abstract][Full Text] [Related]
11. Gold nanoparticles coated with oligomannosides of HIV-1 glycoprotein gp120 mimic the carbohydrate epitope of antibody 2G12.
Marradi M; Di Gianvincenzo P; Enríquez-Navas PM; Martínez-Ávila OM; Chiodo F; Yuste E; Angulo J; Penadés S
J Mol Biol; 2011 Jul; 410(5):798-810. PubMed ID: 21440555
[TBL] [Abstract][Full Text] [Related]
12. N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.
Gray ES; Moore PL; Pantophlet RA; Morris L
J Virol; 2007 Oct; 81(19):10769-76. PubMed ID: 17634239
[TBL] [Abstract][Full Text] [Related]
13. Human antibodies to HIV-1 by recombinant DNA methods.
Burton DR; Barbas CF
Chem Immunol; 1993; 56():112-26. PubMed ID: 8452652
[No Abstract] [Full Text] [Related]
14. AIDS/HIV. A boost for HIV vaccine design.
Burton DR; Weiss RA
Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840
[No Abstract] [Full Text] [Related]
15. Concanavalin A binding to HIV envelope protein is less sensitive to mutations in glycosylation sites than monoclonal antibody 2G12.
Pashov A; MacLeod S; Saha R; Perry M; VanCott TC; Kieber-Emmons T
Glycobiology; 2005 Oct; 15(10):994-1001. PubMed ID: 15917430
[TBL] [Abstract][Full Text] [Related]
16. NMR study and comparison of the antigenic properties of a peptide recognized by two HIV-1 neutralizing antibodies.
Tsang P; Mu X; Wu G; Durda PJ
J Mol Recognit; 1997; 10(6):256-61. PubMed ID: 9770649
[TBL] [Abstract][Full Text] [Related]
17. Novel template-assembled oligosaccharide clusters as epitope mimics for HIV-neutralizing antibody 2G12. Design, synthesis, and antibody binding study.
Wang J; Li H; Zou G; Wang LX
Org Biomol Chem; 2007 May; 5(10):1529-40. PubMed ID: 17571181
[TBL] [Abstract][Full Text] [Related]
18. Electron microscopic and immunochemical analysis of the broadly neutralizing HIV-1-specific, anti-carbohydrate antibody, 2G12.
Roux KH; Zhu P; Seavy M; Katinger H; Kunert R; Seamon V
Mol Immunol; 2004 Aug; 41(10):1001-11. PubMed ID: 15302162
[TBL] [Abstract][Full Text] [Related]
19. HIV vaccine design and the neutralizing antibody problem.
Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
[No Abstract] [Full Text] [Related]
20. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.
Scanlan CN; Pantophlet R; Wormald MR; Ollmann Saphire E; Stanfield R; Wilson IA; Katinger H; Dwek RA; Rudd PM; Burton DR
J Virol; 2002 Jul; 76(14):7306-21. PubMed ID: 12072529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
